Literature DB >> 11641094

Principles of surgical radicality in the treatment of gastric cancer.

F Bozzetti1.   

Abstract

The aim of curative surgery is to perform an RO resection, that is, the volume of resection should encompass the tumor volume in toto and fall in healthy margins. This means maintaining a transection margin 6 cm from the tumor and removing neighboring organs altogether if involved by the tumor. With regard to lymphadenectomy, the adequate number to be retrieved which allows a proper staging, and probably the optimal results, is about 25 lymph nodes.

Entities:  

Mesh:

Year:  2001        PMID: 11641094

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  5 in total

1.  Treatment of resectable gastric cancer.

Authors:  Johan L Dikken; Cornelis J H van de Velde; Daniel G Coit; Manish A Shah; Marcel Verheij; Annemieke Cats
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

2.  D2 lymphadenectomy (over-D1 dissection) for advanced gastric cancer is an evidence-based procedure.

Authors:  Federico Bozzetti
Journal:  J Gastrointest Surg       Date:  2011-06-30       Impact factor: 3.452

Review 3.  Gastric adenocarcinoma: review and considerations for future directions.

Authors:  Bryan J Dicken; David L Bigam; Carol Cass; John R Mackey; Anil A Joy; Stewart M Hamilton
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

4.  R0 resection in the treatment of gastric cancer: room for improvement.

Authors:  Alberto Biondi; Roberto Persiani; Ferdinando Cananzi; Marco Zoccali; Vincenzo Vigorita; Andrea Tufo; Domenico D'Ugo
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

5.  Routine modified D2 lymphadenectomy performance in pT1-T2N0 gastric cancer.

Authors:  John Griniatsos; Hara Gakiopoulou; Eugenia Yiannakopoulou; Nikoletta Dimitriou; Gerasimos Douridas; Afrodite Nonni; Theodoros Liakakos; Evangelos Felekouras
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.